BACKGROUND:

invasive fungal infection is an increasingly common cause of mortality and morbidity in preterm infants. In addition to amphotericin B, a variety of newer antifungal drugs and drug preparations are available for treatment. There is a need to assess their relative merits.

OBJECTIVES:

In preterm infants with suspected or confirmed invasive fungal infection, does treatment with newer Systemic antifungal drugs or drug preparations, versus conventional amphotericin B alone, reduce mortality and adverse neurodevelopmental outcomes?

SEARCH STRATEGY:

We used the standard search strategy of the Cochrane Neonatal Review Group. This included searches of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 3, 2003), MEDLINE (1966 - August 2003), EMBASE (1980 - August 2003), conference proceedings, and previous reviews.

SELECTION CRITERIA:

Randomised and quasi-randomised control trials comparing one antifungal agent or combination of agents with another in preterm infants with suspected or confirmed invasive fungal infection.

DATA COLLECTION AND ANALYSIS:

We extracted the data using the standard methods of the Cochrane Neonatal Review Group, with separate evaluation of trial quality and data extraction by each author, and synthesis of data using relative risk and risk difference. The pre-specified outcomes were death prior to hospital discharge, longer term neurodevelopment, and adverse drug reactions resulting in discontinuation of therapy.

MAIN RESULTS:

We identified only one small trial. This study compared the use of fluconazole with amphotericin B (5-Fluorocytosine added if fungal meningitis present). Three of 11 infants who were treated with fluconazole died and four of 10 infants who were treated with amphotericin B died : Relative risk: 0.68 (95% confidence interval 0.20, 2.33), Risk Difference -0.13 (95% confidence interval -0.53, 0.27) There were not any data on longer term outcomes.

REVIEWER'S CONCLUSIONS:

From this one small study there are insufficient data to favour one antifungal agent or combination to reduce mortality and adverse neurodevelopmental outcomes in preterm infants with suspected or confirmed invasive fungal infection. A large randomised controlled trial is required to compare the newer antifungal preparations with conventional amphotericin B. Further research may also determine the relative convenience and cost effectiveness of the available drugs.

Related Articles
Review Antifungal therapy for newborn infants with invasive fungal infection.
Cochrane Database Syst Rev. 2012
Review Antifungal therapy for newborn infants with invasive fungal infection.
Clerihew L, McGuire W. Cochrane Database Syst Rev. 2012 Jun 13; 6:CD003953. Epub 2012 Jun 13.
Review Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants.
Cochrane Database Syst Rev. 2007
Review Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants.
Clerihew L, Austin N, McGuire W. Cochrane Database Syst Rev. 2007 Oct 17; (4):CD003850. Epub 2007 Oct 17.
Review Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants.
Cochrane Database Syst Rev. 2004
Review Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants.
McGuire W, Clerihew L, Austin N. Cochrane Database Syst Rev. 2004; (1):CD003850.
Review Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants.
Cochrane Database Syst Rev. 2003
Review Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants.
McGuire W, Clerihew L, Austin N. Cochrane Database Syst Rev. 2003; (1):CD003850.
Review Prophylactic oral antifungal agents to prevent systemic candida infection in preterm infants.
Cochrane Database Syst Rev. 2004
Review Prophylactic oral antifungal agents to prevent systemic candida infection in preterm infants.
Austin NC, Darlow B. Cochrane Database Syst Rev. 2004; (1):CD003478.
The use of ciprofloxacin and fluconazole in Italian neonatal intensive care units: a nationwide survey.
BMC Pediatr. 2013
The use of ciprofloxacin and fluconazole in Italian neonatal intensive care units: a nationwide survey.
Pandolfini C, Marco S, Paolo M, Maurizio B. BMC Pediatr. 2013 Jan 7; 13:5. Epub 2013 Jan 7.
Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections.
Eur J Clin Pharmacol. 2013
Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections.
Pandolfini C, Kaguelidou F, Sequi M, Jacqz-Aigrain E, Choonara I, Turner MA, Manzoni P, Bonati M. Eur J Clin Pharmacol. 2013 Apr; 69(4):1031-6. Epub 2012 Oct 5.
Invasive fungal infection in very low birthweight infants: national prospective surveillance study.
Arch Dis Child Fetal Neonatal ...
Invasive fungal infection in very low birthweight infants: national prospective surveillance study.
Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Arch Dis Child Fetal Neonatal Ed. 2006 May; 91(3):F188-92. Epub 2005 Dec 6.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster